Serial 98811655
Live / Applied — First extension granted (statement of use) (as of 29 Sept 2025)
What this means for you
Not registered yet, but its 21 Oct 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98811655
- Mark type
- Design / logo
- Filed
- 21 Oct 2024
- Published for opposition
- 27 May 2025
- Attorney of record
- Brian Focarino
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for the treatment of edema, namely hereditary angioedema; pharmaceuticals for the treatment of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders
- Class 044 — Medical, beauty and agricultural services: Medical services; medical information services; providing a website featuring medical and healthcare information for healthcare professionals, caregivers, patients, and providers in the fields of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders; medical consulting services in the field of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders; healthcare services, namely, providing an online database of medical and healthcare information in the field of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune lymphoproliferative, and rare diseases and disorders, and collecting data and information on autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders for treatment and diagnostic purposes; providing medical and healthcare information concerning the screening, diagnosis, and treatment of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders
Owner
- Ionis Pharmaceuticals, Inc., Carlsbad, CA, US
- Ionis Pharmaceuticals, Inc., Carlsbad, CA, US
Prosecution history
- 03 Feb 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 03 Feb 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 03 Feb 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 03 Feb 2026 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 03 Feb 2026 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 30 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 29 Sept 2025 — SOU EXTENSION 1 GRANTED
- 29 Sept 2025 — SOU EXTENSION 1 FILED
- 29 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 22 Jul 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 27 May 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 27 May 2025 — PUBLISHED FOR OPPOSITION
- 21 May 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 25 Apr 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 23 Apr 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED